Financial Performance - The company's operating revenue for Q1 2025 was ¥191,951,815.38, representing a 4.94% increase compared to ¥182,922,481.69 in the same period last year[4] - The net profit attributable to shareholders was -¥115,452,483.95, a decrease of 71.41% from -¥67,353,495.40 year-over-year[4] - The basic and diluted earnings per share were both -¥0.57, a decline of 72.73% compared to -¥0.33 in the same period last year[4] - The weighted average return on equity was -1.75%, down from -0.91% year-over-year[4] - Net loss for Q1 2025 was CNY 120,770,122.94, compared to a net loss of CNY 69,955,283.74 in Q1 2024, representing an increase in loss of 72.6%[20] - Operating profit for Q1 2025 was CNY -123,486,375.38, worsening from CNY -67,454,742.43 in Q1 2024[19] - The company reported a total comprehensive loss of CNY -128,591,327.44 for Q1 2025, compared to CNY -78,308,185.85 in Q1 2024[20] Cash Flow - The net cash flow from operating activities improved by 74.38%, reaching -¥54,288,610.17, compared to -¥211,864,976.91 in the previous year[4] - Operating cash inflow totaled $276,022,567.96, an increase from $228,718,943.11 in the previous period, reflecting a growth of approximately 20.8%[24] - Cash inflow from investment activities reached $1,466,438,459.32, significantly higher than $539,083,927.86 in the prior period, marking an increase of about 172.6%[25] - Cash inflow from financing activities amounted to $239,000,000.00, up from $105,960,000.00, representing an increase of approximately 125%[25] - The ending cash and cash equivalents balance was $1,038,630,348.81, down from $2,595,292,577.44 year-over-year[25] Assets and Liabilities - Total assets decreased by 4.14% to ¥7,759,161,951.63 from ¥8,094,580,246.54 at the end of the previous year[5] - The company reported a total current assets of RMB 3,583,909,471.49 as of March 31, 2025, down from RMB 3,978,764,707.92 at the end of 2024, representing a decrease of approximately 9.9%[14] - Total liabilities decreased to CNY 1,094,430,122.43 in Q1 2025 from CNY 1,303,147,089.90 in Q1 2024, a decline of 15.9%[16] - The company's total equity decreased to CNY 6,664,731,829.20 in Q1 2025 from CNY 6,791,433,156.64 in Q1 2024, a decrease of 1.9%[16] Research and Development - Research and development expenses totaled ¥58,725,780.47, accounting for 30.59% of operating revenue, down from 39.34% in the previous year[5] - Research and development expenses for Q1 2025 were CNY 58,725,780.47, down 18.3% from CNY 71,964,517.95 in Q1 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,778[9] - The top three shareholders collectively hold 48.56% of the company's shares, with Anji Fulanglai holding 19.5%, Fangs Holdings Limited at 18.75%, and Anji Yongwei at 10.31%[11] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[12] Legal Matters - The company is currently facing a lawsuit from FS Medical Supplies, LLC, claiming damages not less than USD 1 billion, along with additional compensatory damages of at least USD 250 million[12] - The company has engaged legal counsel to respond to the lawsuit and is also pursuing legal action against FS Medical Supplies, LLC in China[13] - As of the report date, the lawsuit has not impacted the company's financial results for the reporting period[13] Inventory and Receivables - Cash and cash equivalents decreased to RMB 2,604,809,193.17 from RMB 3,081,496,804.80, reflecting a decline of about 15.4%[14] - Accounts receivable decreased to RMB 191,096,239.50 from RMB 228,082,280.19, a reduction of about 16.2%[14] - Inventory decreased slightly to RMB 296,948,644.63 from RMB 308,960,712.66, indicating a decrease of around 3.9%[14]

东方生物公告，2025年第一季度营收为1.92亿元，同比增长4.94%；净亏损1.15亿元，去年同期净亏损 6735.35万元。 ...

东方生物在呼吸道感染性疾病检测领域已深耕多年，此前在欧洲市场取得新冠的IVDR专业和家庭自测 证书、新冠/甲流/乙流三联检的IVDR专业和家庭自测证书，以及A族链球菌IVDR专业检测证书。在美 国市场分别取得了新冠检测、新冠/甲流/乙流三联检测、合胞病毒检测、A族链球菌检测等呼吸道检测 的FDA证书。 东方生物在欧美高端市场的呼吸道感染性疾病检测系列产品获得广泛欢迎和高度好评，特别是其新冠/ 甲乙流三联检产品，作为首个获FDA De Novo认证的联检试剂，被美国ABC News列为"2024年度五大医 学突破"之一，目前已在Walgreens等连锁药房上市销售。 值得关注的是，东方生物全球化布局正在提速。目前在美国、英国、加拿大等地已建成生产基地，实 现"本地规模化生产"。公司表示，未来将充分发挥呼吸道检测领域顶尖的研发与生产能力，不断深耕欧 美市场，开拓创新。市场分析人士指出，这种"本地化生产+多重检测技术"的组合策略，既规避了跨境 物流风险，又契合了后疫情时代各国对高效诊断方案的需求。 4月17日，据东方生物官微消息，近日公司自主研发的新冠/甲乙流/合胞病毒/腺病毒抗原联合检测试剂 (胶体金法)通过欧盟 ...

最新一期业绩显示，2024年三季报，公司实现营业收入6.58亿元，同比0.83%；净利润-262156256.43 元，同比-262.17%，销售毛利率34.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)25东方生物-8.98-8.980.6745.92亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743.02亿 来源：金 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-009 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 近日取得以下产品的境外医疗器械注册证，相关公告如下： 一、境外医疗器械注册证的具体情况 | 产品名称 | 证书编号 | 预期用途 | 有效期 | | --- | --- | --- | --- | | | | 本产品用于定性检测鼻拭子中新 | | | COVID-19/Flu A&B/RSV/Adeno Ag | | 冠病毒、甲型流感、乙型流感、 | 2025/4/15 | | Combo Rapid Test Cassette (Swab) | 6188440TD01 | 合胞病毒和腺病毒标本，旨在帮 | - | | 新冠/甲乙流/合胞病毒/腺病毒抗原联 | | 助快速鉴别诊断呼吸系统新冠病 | | | 合检测试剂（胶体金法） | | 毒、甲乙型流感、合胞病毒或腺 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-008 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 及下属全资子公司美国衡健生物科技有限公司（以下简称"美国衡健"）、上海 万子健生物科技有限公司（以下简称"上海万子健"）近期取得以下产品的国内 外医疗器械注册证，相关公告如下： 三、对上市公司的影响 上述产品在国内外市场取证，丰富了公司产品布局，有利于整体市场拓展。 四、风险提示 上述产品的实际销售业绩取决于产品的实际竞争力和市场销售能力，目前尚 无法预测对公司未来经营业绩的影响，敬请投资者注意投资风险。 特此公告。 浙江东方基因生物制品股份有限公司 董 事 会 一、境内医疗器械注册证的具体情况 | 产品名称 | 证书编号 | 预期用途 | 持证人 | 有效期 | | --- | --- | --- | --- | --- | | 游离/总前列腺特异性 | 国械注准 ...

Core Viewpoint - FS Medical Supplies, LLC has filed a lawsuit against Zhejiang Oriental Gene Biological Products Co., Ltd. and its subsidiary, claiming breach of contract regarding a "no circumvention" clause related to COVID-19 testing kits [2][4]. Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Southern District of Texas, with the case number 4:25-CV-1332, and the cause of action is a contract dispute [4][6]. - The plaintiff alleges that the defendants violated the "no circumvention" clause by directly providing COVID-19 testing kits to FS Medical Supplies' customers, resulting in economic losses for the plaintiff [4][5]. - The plaintiff is seeking damages that include a penalty of no less than $1 billion, along with compensatory damages of at least $250 million, and other legal costs [6][7]. Group 2: Company Response and Impact - The company has engaged U.S. legal counsel to analyze the lawsuit's validity and intends to actively respond to the claims, asserting that the plaintiff's breach of contract claims are unfounded [7]. - The company has also initiated legal action against FS Medical Supplies in China, claiming that the framework agreement is invalid due to the plaintiff's lack of medical device operating licenses and false representations [7]. - Currently, the company's operations remain normal, and there are no frozen or restricted assets, indicating that the lawsuit will not impact the company's financial results for 2024, although future impacts remain uncertain [2][7].

证券代码：688298 证券简称：东方生物 公告编号：2025-007 浙江东方基因生物制品股份有限公司 关于有关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： "FS Medical Supplies, LLC"认为公司违反合同约定的"禁止规避"条 款，向美国德克萨斯州南区联邦地区法院提起诉讼，目前尚未开庭审理。 上市公司所处的当事人地位：被告。 影响：公司目前生产经营正常，不存在资产被冻结或受限的情况，本案不 会对公司 2024 年度损益产生影响，但目前无法预判对期后损益的影响。 被告1：浙江东方基因生物制品股份有限公司 被告2：美国衡健生物科技有限公司，系被告1美国全资子公司 （五）诉讼机构名称和所在地：美国德克萨斯州南区联邦地区法院 （六）案件主要事由（以下内容参考原告提交的起诉状中的所述信息） 2020年5月，被告1、被告2与原告签订了《FRAMEWORK PURCHASE AGREEMENT》 （《新冠抗体框架采购协议》），约定东方生物作为生产商与子公司美国衡健共 同作为该合同的制造 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-006 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 上述产品在国内市场取证，丰富了公司在国内市场的产品布局，有利于整体 市场拓展。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 下属全资子公司上海万子健生物科技有限公司（以下简称"上海万子健"）近期 取得以下产品的国内医疗器械注册证，相关公告如下： | 产品名称 | 证书编号 | 预期用途 | 持证人 | 有效期 | | --- | --- | --- | --- | --- | | 糖类抗原15-3检测试 （流式荧光发光法） | | 供医疗机构用于体外定量检测人 体血清中糖类抗原15-3的含量。临 据 | | 2025/3/6 -2030/3/5 | | 剂盒 | 沪械注准 | 床上用于乳腺癌的治疗监测，不作 | | | | | 20252400090 | 为恶性肿瘤早期诊断或确诊的依 | | | | 人附睾蛋白 ...

这一决策标志着东方生物从"人医"到"动保"的双赛道战略正式落地，公司计划通过技术迁移、产业链整 合与全球化布局，打造动物健康领域的全新增长极。 3月10日，东方生物在浙江安吉召开发布会，正式宣布进军动物保健（动保）领域。发布会上，东方生 物还宣布，其控股子公司华信农威研发的蓝耳病灭活疫苗蓝倍安和衣原体基因工程亚单位疫苗孕倍安正 式上市。 打造"人医"+"动保"双赛道战略 "此次进军动保领域，我们已做好充分准备。"方炳良透露，为实现动保领域的快速突破，东方生物采取 了"自主研发+战略并购"的组合拳。 2023年是东方生物在动保领域布局的关键一年。东方生物于当年底获得了新版《中华人民共和国兽药 GMP证书》《中华人民共和国兽药生产许可证》，可开展动宠物免疫学类诊断制品（B类）的生产。当 年，公司通过收购北京华信农威生物科技，获取涵盖猪蓝耳病灭活疫苗、猪圆环病毒灭活疫苗、猪瘟活 疫苗（细胞源）、猪支原体肺炎灭活疫苗等20余种产品的批文与成熟渠道。据悉，华信农威前身为北京 市兽医生物药品厂，借助此次收购，东方生物迅速切入动保疫苗市场，大大缩短了产品研发取证和市场 拓展周期，为布局动保领域赢得了宝贵的时间。 从IVD龙 ...